466 related articles for article (PubMed ID: 20038864)
1. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.
Silva RM; Ruiz-Moreno JM; Rosa P; Carneiro A; Nascimento J; Rito LF; Cachulo ML; Carvalheira F; Murta JN
Retina; 2010 Mar; 30(3):407-12. PubMed ID: 20094007
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
4. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
Varano M; Tedeschi M; Oddone F; Perillo L; Coppè AM; Parravano M
Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks: one-year results of a prospective study.
Ladas ID; Kotsolis AI; Ladas DS; Niskopoulou M; Georgalas I; Papakonstantinou D; Rouvas AA
Retina; 2010 Sep; 30(8):1185-9. PubMed ID: 20539257
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.
Mimoun G; Tilleul J; Leys A; Coscas G; Soubrane G; Souied EH
Am J Ophthalmol; 2010 Nov; 150(5):692-700.e1. PubMed ID: 20719301
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
11. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
12. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
Sabry D; Gad MA; Enam KM
Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
[TBL] [Abstract][Full Text] [Related]
13. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
15. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
Scupola A; Tiberti AC; Sasso P; Savastano MC; Mastrocola A; Marangoni D; Minnella AM; Falsini B; Balestrazzi E
Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
[TBL] [Abstract][Full Text] [Related]
16. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
18. [Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results].
Cornut PL; Poli M; Feldman A; El Chehab H; Swalduz B; Burillon C; Denis P
J Fr Ophtalmol; 2010 May; 33(5):327-33. PubMed ID: 20452098
[TBL] [Abstract][Full Text] [Related]
19. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
